PHASE II TRIAL WITH RFS2000 IN PATIENTS (PTS) WITH ADVANCED AND/OR METASTATIC BREAST CANCER (MBC)

被引：0
|
作者：
Sorio, R. [1 ]
Chollet, P. [2 ]
Caponigro, F. [3 ]
Carteni, G. [4 ]
Sealone, S. [1 ]
Crivellari, D. [1 ]
Magri, M. D. [1 ]
Adank, S. J. [5 ]
Veronesi, A. [1 ]
机构：
[1] IRCCS, CRO, Aviano, Italy
[2] Ctr J Perrin, Clermont Ferrand, France
[3] IRCCS, Ist Pascale, Naples, Italy
[4] AO Cardarelli, Naples, Italy
[5] NDDO Oncol, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [21] A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer MBC
    Bensalem, A
    Bouzid, K
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 1) : S21 - S21
  • [22] Phase II clinical trial of ixabepilone in metastatic breast cancer (MBC) patients previously untreated with taxanes.
    Denduluri, N.
    Lee, J. J.
    Walshe, J. M.
    Yang, S. X.
    Vatas, U.
    Chow, C. K.
    Steinberg, S. M.
    Cox, M. C.
    Low, J. A.
    Swain, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 40S - 40S
  • [23] MULTICENTER, PHASE II STUDY OF LAROTAXEL IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC) PROGRESSING AFTER ANTHRACYCLINES, TAXANES AND CAPECITABINE
    Ozguroglu, M.
    Mansutti, M.
    Kerr, R.
    Awada, A.
    Rha, S. Y.
    Im, Y. H.
    Perez Manga, G.
    Germann, N.
    Fumoleau, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 69 - 69
  • [24] A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)
    A Bensalem
    K Bouzid
    Breast Cancer Research, 7
  • [25] Clinical and safety data of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer (MBC).
    Mundhenke, Christoph
    Schem, Christian
    Bauerschlag, Dirk Olaf
    Weigel, Marion T.
    Wenners, Antonia Sophie
    Schaefer, Fritz Werner
    Tiemann, Katharina
    Hanson, Sven
    Muth, Mathias
    May, Christoph
    Jonat, Walter
    Maass, Nicolai
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC)
    Peacock, N.
    Saleh, M.
    Bendell, J.
    Rose, A. A.
    Dong, Z.
    Siegel, P. M.
    Crowley, E.
    Simantov, R.
    Vahdat, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC)
    Hamilton, Erika P.
    Dosunmu, Ololade
    Shastry, Mythili
    Finney, Lindsey
    Sellami, Dalila B.
    Sternberg, David W.
    Wright-Browne, Vance
    Toppmeyer, Deborah
    Gwin, William R.
    Thaddeus, J. Thaddeus
    Cultrera, Jennifer L.
    Bagegni, Nusayba Ali
    Khoury, Katia
    Heeke, Arielle Lutterman
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors
    M.J.A. de Jonge
    J.P. Droz
    L. Paz-Ares
    A.T. van Oosterom
    R. de Wit
    P. Chollet
    B. Baron
    D. Lacombe
    K. Mettinger
    P. Fumoleau
    Investigational New Drugs, 2004, 22 : 329 - 333
  • [29] Mitoxantrone and methotrexate (MM) in elderly patients (pts) with metastatic breast cancer (MBC)
    van Veelen, H
    Tjabbes, T
    Bong, SB
    Piersma, H
    Runhaar, EA
    Vermeer, RJ
    Scholtens, T
    ANNALS OF ONCOLOGY, 1998, 9 : 20 - 20
  • [30] Phase II trial of ixabepilone (Ixa) and dasatinib (D) for treatment of metastatic breast cancer (MBC)
    Schwartzberg, L. S.
    Tauer, K. W.
    Schnell, F. M.
    Hermann, R.
    Rubin, P.
    Christianson, D.
    Weinstein, P.
    Epperson, A.
    Walker, M.
    CANCER RESEARCH, 2012, 72
12345